SAB Biotherapeutics, Inc.

Contributing Author

Recent Articles by SAB Biotherapeutics, Inc.

Jan-07	SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director SABS GlobeNewswire
Jan-06	SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference SABS GlobeNewswire
Dec-18	First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D SABS GlobeNewswire
Dec-17	SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D SABS GlobeNewswire
Dec-08	SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management SABS GlobeNewswire
Nov-13	SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights SABS GlobeNewswire
Nov-04	SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 SABS GlobeNewswire
Nov-04	SAB BIO to Participate in Upcoming Investor Conferences SABS GlobeNewswire
Sep-19	SAB BIO Highlights Data in Multiple Presentations at EASD SABS GlobeNewswire
Sep-03	SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes SABS GlobeNewswire
Aug-07	SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates SABS GlobeNewswire
Jul-21	SAB BIO Announces Oversubscribed $175 Million Private Placement SABS GlobeNewswire
May-09	SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates SABS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.